Security
Evotec SE American Depositary Shares · EVO
EVONASDAQotherCurrentCIK 1412558Updated Oct 6, 2026
Name history
Evotec AG · through Sep 23, 2021
EVO price & chart
Loading TradingView…
NASDAQ:EVO on TradingView ↗About the company
Biologics, Inc. Just - Evotec Biologics, wholly owned by Evotec SE, is a first-to-industry biologics platform company that leverages AI/ML technologies and world-leading molecular design, cell line development, process intensification and continuous manufacturing strategies to advance biotherapeutics from discovery through clinical stages to commercial launch. The Just - Evotec Biologics team combines deep industry experience in the fields of data, protein, process, and manufacturing sciences including automation with highly integrated and flexible capabilities to break through the scientific and economic barriers associated with the development of protein therapeutics. Our focus is to accelerate and expand access to biotherapeutics through scientific and technological innovation for our proprietary projects and on behalf of our partners. Learn more at www.just-evotecbiologics.com.
In the news
Recent filings
Show 5 more recent filings
Financials
FY 2024 · EURSource
Source
Source
cash flow · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Profit or LossEUR | -196,078,000Source | -83,913,000Source | -175,655,000Source | 215,510,000Source |
| Additional Financial Items | ||||
| AdjustmentsForCurrentTaxOfPriorPeriodEUR | -328,000Source | 2,666,000Source | -156,000Source | 4,095,000Source |
| AdjustmentsForDecreaseIncreaseInTradeAccountReceivableEUR | — | — | -38,429,000Source | -48,032,000Source |
| AdjustmentsForGainLossOnDisposalOfInvestmentsInSubsidiariesJointVenturesAndAssociatesEUR | -8,648,000Source | — | — | — |
| AdjustmentsForIncomeTaxExpenseEUR | 2,102,000Source | 3,320,000Source | — | — |
| AdjustmentsForSharebasedPaymentsEUR | 5,035,000Source | 9,630,000Source | 9,919,000Source | 7,805,000Source |
| GoodwillEUR | 282,854,000Source | 275,635,000Source | 274,819,000Source | 257,569,000Source |
| IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesEUR | -76,083,000Source | 12,902,000Source | — | — |
| IncreaseDecreaseInWorkingCapitalEUR | 68,207,000Source | 9,944,000Source | — | — |
| InterestPaidClassifiedAsFinancingActivitiesEUR | 5,920,000Source | 12,853,000Source | — | — |
| InterestPaidClassifiedAsOperatingActivitiesEUR | — | — | 9,798,000Source | 5,429,000Source |
| InterestReceivedClassifiedAsOperatingActivitiesEUR | — | — | 3,026,000Source | 1,106,000Source |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesEUR | 24,124,000Source | 22,446,000Source | 19,046,000Source | 20,665,000Source |
| ProceedsFromBorrowingsClassifiedAsFinancingActivitiesEUR | 900,000Source | 219,923,000Source | — | 30,791,000Source |
| ProceedsFromIssuingSharesEUR | — | — | 355,000Source | 403,126,000Source |
| ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivitiesEUR | 2,000,000Source | 530,000Source | — | — |
| PurchaseOfIntangibleAssetsClassifiedAsInvestingActivitiesEUR | 14,769,000Source | 2,677,000Source | — | — |
| RepaymentsOfBorrowingsClassifiedAsFinancingActivitiesEUR | 128,849,000Source | 112,880,000Source | 34,067,000Source | 16,018,000Source |
income statement · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Cost of Goods and Services Sold | — | — | — | — |
| Selling, General and Administrative ExpenseEUR | 188,201,000Source | 169,610,000Source | 156,190,000Source | 105,445,000Source |
| Total RevenueEUR | 796,967,000Source | 781,426,000Source | 751,448,000Source | 618,034,000Source |
| Additional Financial Items | ||||
| ApplicableTaxRatenumber | 0.32Source | 0.32Source | 0.32Source | 0.32Source |
| AverageEffectiveTaxRatenumber | -0.01Source | -0.04Source | -0.14Source | 0.09Source |
| BasicEarningsLossPerShareEUR/shares | -1.11Source | -0.47Source | -0.99Source | 1.3Source |
| CurrentTaxExpenseIncomeEUR | 7,761,000Source | 5,251,000Source | 14,132,000Source | 12,309,000Source |
| DeferredTaxExpenseIncomeRecognisedInProfitOrLossEUR | -5,331,000Source | -4,597,000Source | 7,722,000Source | 5,066,000Source |
| DepreciationRightofuseAssetsEUR | 21,530,000Source | 21,075,000Source | 18,659,000Source | 15,829,000Source |
| DilutedEarningsLossPerShareEUR/shares | -1.11Source | -0.47Source | -0.99Source | 1.3Source |
| EmployeeBenefitsExpenseEUR | 458,738,000Source | 377,587,000Source | 388,050,000Source | 319,353,000Source |
| ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsedEUR | 57,000Source | 62,000Source | 50,000Source | 56,000Source |
| ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsedEUR | 283,000Source | 236,000Source | 476,000Source | 839,000Source |
| GrossProfitEUR | 114,881,000Source | 175,051,000Source | 174,065,000Source | 151,543,000Source |
| ImpairmentLossRecognisedInProfitOrLossGoodwillEUR | 0Source | 0Source | 0Source | 0Source |
| ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillEUR | — | — | — | 683,000Source |
| IncomeTaxExpenseContinuingOperationsEUR | 2,102,000Source | 3,320,000Source | 21,698,000Source | 21,470,000Source |
| InterestExpenseEUR | — | — | 13,150,000Source | 9,254,000Source |
| InterestExpenseOnLeaseLiabilitiesEUR | 4,727,000Source | 5,831,000Source | 3,841,000Source | 3,728,000Source |
| OtherFinanceCostEUR | 11,699,000Source | 11,739,000Source | — | 198,000Source |
| OtherIncomeEUR | 52,700,000Source | 64,793,000Source | 81,582,000Source | 73,472,000Source |
| ProfitLossAttributableToOwnersOfParentEUR | — | — | -175,655,000Source | 215,510,000Source |
| ProfitLossBeforeTaxEUR | -193,977,000Source | -80,593,000Source | -153,957,000Source | 236,980,000Source |
| ProfitLossFromOperatingActivitiesEUR | -142,522,000Source | -47,507,000Source | 20,850,000Source | 40,996,000Source |
| ResearchAndDevelopmentExpenseEUR | 50,857,000Source | 68,529,000Source | 76,642,000Source | 72,200,000Source |
| RevenueFromInterestEUR | — | — | 8,336,000Source | 2,272,000Source |
Filing attachments
tm2627582d1_ex99-1.htm · 6-K · 2026-10-14
Exhibit 99.1 Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014 Ad hoc: Evotec announces preliminary nine-months 2026 results above market expectations, reaffirming full-year 2026 guidance Hamburg, Germany - Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced preliminary unaudited financial results for first nine months of 2026. Full financial results for the third quarter and the first nine months of 2026 will be published on Nov…
Read attachment ↗tm2626558d1_ex99-1.htm · 6-K · 2026-09-29
Exhibit 99.1 Evotec Announces Chief Scientific Officer Transition Dr. Cord Dohrmann to step down as of September 30, 2026 ─────────────────────────────────────────────────────── Search ongoing for a successor Hamburg, Germany, September 29, 2026 - Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced that Chief Scientific Officer (CSO) Dr. Cord Dohrmann will step down effective September 30, 2026. The decision for Dr. Dohrmann to step down from his position was made…
Read attachment ↗tm2625085d1_ex99-1.htm · 6-K · 2026-09-09
Exhibit 99.1 Just - Evotec Biologics Advances U.S. Department of War Antibodies Against Orthopoxvirus into Phase 1 Clinical Studies First-in-human Phase 1 study initiated for investigational antibodies targeting orthopoxviruses developed under U.S. Department of War Accelerated Antibodies Program Supports development of countermeasures against orthopoxviruses, a high-priority biological threat family that includes viruses responsible for smallpox Delivers integrated process develo…
Read attachment ↗tm2623114d1_ex99-1.htm · 6-K · 2026-08-13
Exhibit 99.1 For further information, please contact: Dr. Sarah Fakih, EVP Head of Global Communications and Investor Relations, sarah.fakih@evotec.com, M. +49.(0)151 70 688 784, www.evotec.com INTERIM STATEMENT 6M 2026 HIGHLIGHTS 4 D&PD NET SALES1 EXCLUDING STRATEGIC PARTNERSHIPS INCREASED BY 28% YOY, REFLECTING STRONG CUSTOMER ENGAGEMENT AND COMMERCIAL EXECUTION ─────────────────────────────────────────────────────────────────────────────────────────────── …
Read attachment ↗tm2623114d1_ex99-2.htm · 6-K · 2026-08-13
Exhibit 99.2 Evotec Announces Second Quarter and First Half 2026 Results: Growing Commercial Momentum H1 2026 financial performance: Q2 and H1 Group revenues of €143.5 m and €300.1 m, respectively (Q2: €146.3 m, H1: €313.2 m at CER); adj. Group EBITDA of -€20.8 m and -€42.7 m, respectively (Q2: -€18.6 m, H1: -€37.4 m at CER) Updated FY 2026 outlook: Expected Group revenues of €570 to €610 m (€595 to 635 m CER) and adj. Group EBITDA of -€70 to -€105 m (-€60 to -€90 m CER), comp…
Read attachment ↗tm2620355d1_ex99-1.htm · 6-K · 2026-07-14
Exhibit 99.1 Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014 Ad hoc: Evotec Announces Preliminary Second Quarter and First Half 2026 Results and Updates Full-Year 2026 Outlook Hamburg, Germany - Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced preliminary unaudited financial results for the second quarter and first half of 2026 and updated its full-year 2026 outlook. Full financial results for the second quarter and first ha…
Read attachment ↗